Stock Analysis
AlphaHelix Molecular Diagnostics (NGM:ALPH) First Quarter 2024 Results
Key Financial Results
- Revenue: kr5.67m (down 33% from 1Q 2023).
- Net loss: kr2.46m (loss widened by 343% from 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
AlphaHelix Molecular Diagnostics shares are down 7.1% from a week ago.
Risk Analysis
You should learn about the 5 warning signs we've spotted with AlphaHelix Molecular Diagnostics (including 4 which are concerning).
Valuation is complex, but we're helping make it simple.
Find out whether AlphaHelix Molecular Diagnostics is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NGM:ALPH
AlphaHelix Molecular Diagnostics
AlphaHelix Molecular Diagnostics AB (publ) designs, develops, and distributes diagnostics products in the Nordic region and internationally.
Adequate balance sheet and slightly overvalued.
